Niemann-Pick Type C1 (NPC1) disease is a rare neurovisceral, cholesterol-sphingolipid lysosomal storage disorder characterized by ataxia, motor impairment, progressive intellectual decline, and dementia. The most prevalent mutation, NPC1
Introduction
Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disease caused by a defect in egress of cholesterol and sphingolipids out of lysosomes, which results in a broad array of neurovisceral pathological changes including Purkinje cell death in the cerebellum. Ninety-five percent of NPC disease results from mutations in the NPC1 gene, whereas the remaining 5% is attributed to defects in NPC2 (Millat et al., 1999; Walkley and Suzuki, 2004) . NPC patients typically present in early childhood with progressive impairment of motor and intellectual function and usually die within the first two decades of life . There are currently no Food and Drug Administration-approved therapies for this disorder.
The NPC1 gene encodes a polytopic, highly glycosylated transmembrane protein that localizes to the limiting membrane of the late endosome/lysosome (Carstea et al., 1997; Davies and Ioannou, 2000) . NPC1 protein binds unesterified cholesterol within the lysosome, interacting with NPC2 and facilitating cholesterol egress Infante et al., 2008; Kwon et al., 2009) . Cells harboring mutations in NPC1 sequester unesterified cholesterol in lysosomes and exhibit impairment of mobilization and re-esterification of LDL cholesterol (Neufeld et al., 1999; Wojtanik and Liscum, 2003) .
The most common NPC1 mutation, I1061T (NPC1 I1061T ), represents 15-20% of all human disease alleles (Millat et al., 1999; Davies and Ioannou, 2000; Park et al., 2003) . This mutation results in misfolded NPC1 protein, which is targeted for ERassociated degradation (Gelsthorpe et al., 2008) . Overexpression of NPC1 I1061T protein results in lysosomal localization of mutant protein and complementation of the mutant phenotype, likely caused by a small proportion of NPC1 I1061T protein that assumes proper conformation and escapes ER quality control checkpoints (Gelsthorpe et al., 2008) . Recently, histone deacetylase (HDAC) inhibitors have been shown to increase synthesis of NPC1 I1061T protein and cholesterol egress from lysosomes (Kim et al., 2007; Munkacsi et al., 2011; Pipalia et al., 2011) . These findings raise the possibility that small moleculebased proteostatic therapies might stabilize mutant NPC1 proteins and have the potential to provide clinical benefit.
Development of proteostatic therapies for NPC1 disease requires testing candidate therapies in a suitable disease model. Many of the prominent neuropathological features of human NPC disease are modeled in the BALB/c Npc1 nih (Npc1 Ϫ/Ϫ ) mouse, but this model does not synthesize NPC1 protein and, therefore, is not amenable to proteostatic therapies (Pentchev et al., 1980; Morris et al., 1982; Shio et al., 1982; Higashi et al., 1993; ). An npc1 pf/pf knock-in mouse that ablates cholesterol binding in the NPC1 N-terminal domain was recently generated, but the P202A/F203A mutations result in complete loss of NPC1 function and do not destabilize the mutant protein . A second naturally occurring mouse model, Npc1 nmf164 , expresses a D1005G amino acid substitution in the NPC1 protein; however, the D1005 residue is not conserved in human protein, and there is no evidence that the mutation affects protein folding or stability (Maue et al., 2012) . To address the need for an animal model in which to test proteostatic therapies for NPC1 disease, we generated an Npc1 tm(I1061T)Dso knock-in mouse model (referred to as Npc1 I1061T ). This novel model faithfully recapitulates disease caused by the human NPC1 I1061T mutation and may prove useful for preclinical evaluation of proteostatic therapies for NPC1 disease.
Materials and Methods

Generation of Npc1
tm(I1061T)Dso knock-in mice. The murine Npc1 genomic locus was inserted into a mouse 129 bacterial artificial chromosome (BAC) construct (BAC identification number bMQ-398C12). The I1061T mutation, ATA to ACA at amino acid 1061 in exon 21, was introduced via galactokinase (galK)-based recombineering as described previously (Warming et al., 2005) . A silent mutation was also introduced at alanine 1058 (GCT to GCC) to engineer an MspI restriction site for genotyping. A loxP site was inserted via recombineering (Lee et al., 2001) , within a nonconserved region ϳ220 bp upstream of exon 12, eliminating a wild-type (WT) NdeI site. A loxP-frt-pGK-neomycin-frt expression cassette was inserted within a nonconserved region ϳ800 bp downstream of exon 20, serving as positive selection in embryonic stem (ES) cells. Conditional deletion of exons 14 -20 introduces a frameshift and multiple premature stop codons, providing the option of conditional Npc1 knockout for future experiments. The targeting vector was generated from the engineered BAC using gap repair, inserted into a plasmid vector containing a diph- I1061T mouse model. A, Diagram of the knock-in targeting vector, the WT NPC1 allele, and the resulting recombined allele. B, Restriction digest of genomic DNA, followed by Southern blotting in ES cells. Genomic DNA from WT and Npc1 ϩ/I1061T mice was digested with NdeI and HindIII to produce a 6.1 kb band from the WT allele and a 7.6 kb band from the knock-in. C, Electropherogram of NPC1 cDNA sequence data, showing the ATA-to-ACA mutation at the 1061 amino acid position. theria toxin cassette for negative selection in 129 ES cells (Lee et al., 2001) , and linearized for ES cell electroporation with AscI. PCR analysis was performed using an external primer 3Ј of the short arm and an internal primer within the neomycin cassette. Southern blot analysis of NdeI or NdeI/HindIII digestion products confirmed homologous recombination in the ES cells. Cells were injected into C57BL/6 blastocysts and implanted in C57BL/6 mothers. Resulting chimeras were then bred with FLPeR C57BL/6 mice (catalog #003946; The Jackson Laboratory) to excise the neo cassette. Excision was confirmed via PCR and HindIII digestion. These mice were then backcrossed into The Jackson Laboratory C57BL/6 background for five generations. Mice were kept in a controlled animal facility and given standard chow and water ad libitum. Weaning occurred between 3 and 4 weeks. Experimental procedures were approved by the Washington University and University of Michigan Animal Studies Committees and were conducted in accordance with the USDA Animal Welfare Act and the Public Health Service Policy for the Humane Care and Use of Laboratory Animals.
Genotyping. Npc1 tm(I1061T)Dso (referred to as Npc1 I1061T ) knock-in mice were identified via a PCR-based genotyping method with the following primers: forward, 5Ј-tgatctgcacacttggaaccgag-3Ј; and reverse, 5Ј-cactgccttgagcagcatctcag-3Ј. The WT Npc1 allele produced a 200 bp fragment, whereas the knock-in allele produced a 234 bp fragment. MspI restriction digest also confirmed the presence of the I1061T point mutation.
Functional evaluation of mice. For animal survival and behavioral studies, the groups were balanced between males and females (Npc1 Ϫ/Ϫ mouse studies, four males/four females; Npc1 I1061T mouse studies, six males/six females), and the general clinical condition of the mice was monitored daily. Mice were weighed weekly beginning at 4 weeks of age until they died. Death was defined as either being found dead in the cage or by the inability to eat or drink on their own, necessitating euthanasia. Cerebellar function was evaluated weekly by measuring retention time on a rotating drum at 15 rpm (Langmade et al., 2006) . For each run, cumulative retention time on the drum was determined for three consecutive attempts (a maximum of 180 s per attempt). Mice were tested in the morning and in the afternoon, and the rotarod score was determined as the highest cumulative retention time for an individual session.
Real-time quantitative RT-PCR. Mice were killed, and liver and cerebellum were flash-frozen in liquid nitrogen and stored at Ϫ80°C. RNA was harvested by homogenization in Trizol reagent (Invitrogen) as per the manufacturer's protocol. cDNA libraries were made via the Superscript III First Strand Synthesis System (Invitrogen) with provided oligo dT primers. Real-time quantitative RT-PCR (RT-qPCR) analysis was performed with reported primer sequences (Li et al., 2005; Liu et al., 2010) . Relative quantification of gene expression was performed using the comparative threshold (C T ) method as described previously (Millard et al., 2005) . Fold changes in the mRNA expression level were calculated following normalization to 36B4, a ribosomal mRNA.
Protein preparation and Western blot analysis. Protein was harvested from flash-frozen liver and brain tissues as described previously (Newberry et al., 2003) . Cultured cells were harvested in RIPA buffer (10 mM Tris-Cl, pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) with Complete Protease Inhibitor Mixture (Roche) and 1 mM phenylmethylsulfonyl fluoride and incubated on ice for 10 min. Postnuclear supernatant was obtained by centrifuging for 10 min at 12,000 ϫ g at 4°C. Protein concentration was quantified using the BCA Protein Assay kit (Pierce). Nonboiled protein samples were resolved by 7.5% SDS-PAGE under reducing conditions. Proteins were transferred onto polyvinylidene difluoride (0.45 mm; Millipore) using a semidry electroblotter (Owl Scientific). Western blot analysis was performed using an affinity-purified rabbit anti-human NPC1 antibody at a dilution of 1:2500 and rabbit anti-human HSP90 (Enzo/Stressgen) at a dilution of 1:5000. Detection was performed by chemiluminescence using a peroxidase-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories) at 1:5000.
Endoglycosidase treatments. Liver and brain tissues were isolated and protein was harvested as described previously (Newberry et al., 2003) .
Protein samples were incubated with endoglycosidase H (New England Biolabs) or PNGaseF (New England Biolabs) for 7 h at 37°C in 5 mM sodium phosphate with 1% NP-40.
Hepatocyte isolation and cycloheximide treatment. Mouse hepatocytes were isolated from postnatal day 35 (P35) mice and cultured as described previously (Chen et al., 2000) . NPC1
I1061T homozygous fibroblasts 59413 were obtained from Dr. John O'Brien (Mayo Clinic, Rochester, MN) and cultured as reported previously (Gelsthorpe et al., 2008) . At 24 h after plating, cells were treated with 30 g/ml cycloheximide (CHX; Sigma) in growth medium for the indicated time periods, lysed, and subjected to Western blot analysis as described above.
Immunohistochemistry of murine tissues. Mouse tissues were collected at indicated time points. Mice were perfused with 0.9% saline solution, ), and homozygous (Npc1
I1061T
) mice, recorded weekly beginning at week 4. C, Rotarod testing was used to evaluate motor function on a constant 15 rpm rotating drum. Values reported are the sum of the time on the rotarod for 3 consecutive attempts. *pϽ0.05; **pϽ0.001. and tissue blocks were immediately drop-fixed in 4% paraformaldehyde overnight at 4°C. Tissues were then rinsed and stored in 0.1 M phosphate buffer at 4°C. Tissues were sectioned (35 m) and stained as described previously . Primary antibodies ␣-GM2 ganglioside (mouse, in house) and ␣-calbindin (mouse, Sigma) were used at 1:200 and 1:3000, respectively. Biotinylated ␣-mouse IgM and ␣-mouse IgG secondary antibodies (both from Vector Laboratories) were diluted 1:200. Sections were evaluated, and wide-field images were acquired on a Zeiss AxioSkop2 Plus microscope with an AxioCam MRc CCD (AxioVision 4.4 software) using 2.5ϫ (NA 0.075) or 10ϫ (NA 0.3) objectives or on an Olympus AX70 microscope with a MagnaFire CCD (MagnaFire version 2.1 software) using a 10ϫ (NA 0.3) objective. Images were processed, and figures were prepared in ImageJ (version 1.48; NIH) and Adobe Photoshop (version CS6). Images were corrected for nonspecific background and, if necessary, stretched to fit the full dynamic eight-bit range.
Immunofluorescence staining of murine tissues. Mouse tissues were harvested and sectioned as described above. Primary antibodies were used at the following dilutions: ␣-GM2 ganglioside (mouse, in house), 1:25; ␣-calbindin (mouse, Sigma), 1:3000; ␣-calbindin (rabbit, Millipore), 1:800; ␣-NeuN (mouse, Millipore Bioscience Research Reagents), 1:1000; ␣-CD68 (rat, AbD Serotec), 1:1000; ␣-GFAP (mouse, Sigma), 1:3000. Goat secondary antibodies (1:250, all from Invitrogen) targeting the following species/isotypes and conjugated to Alexa Fluor fluorophores (AF) were ␣-mouse IgM AF546, ␣-rat IgG AF488, ␣-mouse IgG AF546, ␣-mouse IgG AF488, and ␣-rabbit IgG AF488. To avoid cross-reactivity with the primary ␣-GM2 ganglioside antibody, goat ␣-mouse IgG AF488 (1:450; Jackson ImmunoResearch Laboratories) was used. Filipin complex from Streptomyces filipinensis (Sigma) was dissolved in DMSO (Sigma) and used at a final concentration of 0.05 mg/ml. Confocal images were acquired on a Zeiss 510 Duo V2 laserscanning microscope using 20ϫ (NA 0.80) or 63ϫ oil (NA 1.4) objectives and 351, 488, and 543 nm excitation lasers. Image acquisition conditions (laser intensities, pinhole size, dichroic mirrors, bandpass filters, photomultiplier gains) were kept constant for particular combinations of dyes. Emission wavelength filtering was set to minimize cross talk, and excitation and emission collection was performed sequentially for individual fluorophores. Selected Z stacks are presented as single-plane maximumintensity projections (MIPs). I1061T (left)andNpc1 Ϫ/Ϫ (right)cholesterolandGM2gangliosidestorageintheneuronalcellbodies(NeuNϩ),aswell aswithindistendedinitialaxonalsegments(meganeurites,whitearrows).C,Microglial(CD68ϩ)andastrocytic(GFAPϩ)labelinginNpc1
I1061T micecomparedwithNpc1 Ϫ/Ϫ miceinasegmentofdeepsomatosensorycortex (layerVI),subcorticalwhitematter,andtheadjoiningCA1segment.ImagesareMIPsof4.8-m-thickZstacks.WM,Whitematter;ctx,cortex;CA1,CA1regionofhippocampus.Scalebars:A,100m;B,5m;C,50m.
traced/counted using an Olympus BX51 microscope equipped with 4ϫ (NA 0.13), 10ϫ (NA 0.30), and 20ϫ (NA 0.50) objectives and Stereo Investigator software (MBF Biosciences). Densities are shown as the number of Purkinje cells/1 mm of Purkinje cells layer length. Statistical comparisons were calculated for average density values in cerebellar lobules, grouped based on sagittally projected transverse cerebellar zones as described previously (Sillitoe and Joyner, 2007) .
Isolation of murine embryonic fibroblasts. Mouse embryos were isolated at day 13.5 and placed in PBS. The head and entrails were removed, and the embryo was minced into small chunks. Chunks were transferred to a 50 ml conical, and 1 ml of trypsin (0.25% in EDTA) was added, pipetted to initiate disaggregation. Another 0.5 ml of trypsin was added, and the tissue was digested 15 min at room temperature with occasional vortexing. The reaction was then neutralized with medium (10% heatinactivated fetal serum, 1% nonessential amino acids, 150 M 1-thioglycerol in DMEM), and supernatant was taken as a sample. Samples were centrifuged at 1000 rpm for 10 min to pellet cells. Isolated cells were then plated into flasks, ϳ1.25 embryos per T150.
Cell culture immunofluorescence. Murine embryonic fibroblasts (MEFs) were plated on 12 mm circular coverslips in medium in 24-well plates at 5 ϫ 10 4 cells per well. Twenty-four hours after plating, cells were fixed in 4% paraformaldehyde for 20 min and permeabilized with 0.2% Tween 20 with 10% normal goat serum in PBS for 30 min. Cells were stained with ␣-NPC1 antibody (rabbit, 1:250, in house), ␣-LAMP1 (rat, 1:500, University of Iowa Hybridoma Bank), and filipin (0.05 mg/ml, Sigma) for 1 h. Cells were then incubated with rabbit Alexa Fluor 594 and rat Alexa Fluor 488 for 1 h and mounted with Slowfade (Invitrogen). Images were captured with the 63ϫ objective on a laser-scanning confocal microscope (LSM 700 URGB two-channel system; Carl Zeiss) with 405, 488, 555, and 635 nm solid-state lasers coupled to an Axio Imager M2 microscope with a motorized stage and Zen software. Images were captured with channel pinholes adjusted to 1 Airy unit.
Metabolomics. Sample preparation, instrumentation, and quantification of lipids were performed by tandem mass spectrometry as described previously (Fan et al., 2013) . For Npc1 I1061T heat maps, data were normalized to the average of the P28 WT values for each lipid, and Z scores for each lipid were generated as reported previously (Fan et al., 2013) . Heat maps for the strain comparison (see Fig. 10 ) were generated by normalizing data to C57BL/6 WT and then calculating Z scores.
Treatment of Npc1 fibroblasts with suberanilohydroxamic acid. WT and Npc1
I1061T MEFs were plated in 10 cm tissue culture plates in growth medium supplemented with 10% FBS. After a 24 h incubation, the cells were treated with 10 M suberanilohydroxamic acid (SAHA) or DMSO (vehicle control) for 72 h in growth medium supplemented with 5.5% FBS and harvested for Western blot analysis as described previously (Pipalia et al., 2011) .
Statistics. Statistical significance was calculated via the two-tailed t test using the Holm-Sidak method, with p Ͻ 0.05 considered to be significant. In addition to the t test, a Bonferroni's post-test correction for multiple comparison errors was applied to all metabolomic data to determine significance between genotypes.
Results
Npc1
I1061T knock-in mice have decreased lifespan, reduced body weight, and impaired motor function To generate the targeting vector to introduce the I1061T point mutation into the murine Npc1 locus, we used a BAC construct and galK-based recombineering as described (Fig. 1A) . Recom- bination events were confirmed in ES cells by restriction digest and Southern blotting (Fig. 1B) , and the T3179C mutation resulting in the I1061T substitution was confirmed by sequencing of the mRNA (Fig. 1C) . ES cells harboring the mutant allele were then injected into pregnant C57BL/6 females, and chimeras were bred with FLPeR C57BL/6 mice to excise the neomycin cassette. Analyses were performed on offspring backcrossed a minimum of five generations into the C57BL/6 background. When compared with the Npc1 Ϫ/Ϫ model, Npc1 I1061T mice live 59% longer, with an average lifespan of 125 d, consistent with expression of a partially functional NPC1 protein ( Fig. 2A) . Like Npc1 Ϫ/Ϫ mice, Npc1 I1061T mice have significantly lower body weight compared with their WT littermates, and growth curves begin to diverge at 10 weeks, revealing progressive weight loss during later stages of disease (Fig. 2B) . At approximately 8 weeks of age, there is onset of a visible resting tremor in Npc1 I1061T mice, and by 12 weeks, the mice are no longer able to maintain balance on a rotating rod, a test of motor coordination (Fig. 2C ).
I1061T mice exhibit neurological and hepatopathological hallmarks of NPC disease The progressive loss of motor coordination in NPC1 disease is a well established consequence of the stereotypical Purkinje cell loss in the cerebellum (Higashi et al., 1993) . To determine whether the neurological phenotype we observed in the Npc1 I1061T mice was associated with Purkinje cell degeneration, we performed calbindin D immunohistochemistry to visualize these neurons in parasagittal cerebellar sections from P28, P63, and P105 mice. In contrast to WT littermates, cerebella from Npc1 I1061T mice showed progressive, age-dependent loss of calbindin D staining, predominantly in the anterior lobules, indicating loss of Purkinje cells (Fig. 3 A, B) . The progressive Purkinje cell degeneration was also reflected in the age-dependent reduction in calbindin D mRNA expression (Fig. 3C) . In the cerebella of P63 and P105 mice, there was a significant loss of Purkinje cells in anterior (P63, 58% reduction, p Ͻ 0.01; P105, 91% reduction, p Ͻ 0.001), central (P105, 80% reduction, p Ͻ 0.001), posterior (P105, 65% reduction, p Ͻ 0.001), and nodular (P105, 41% reduction, p Ͻ 0.001) zones but no appreciable Purkinje cell loss in lobule X, which is generally preserved even in end-stage disease ( Fig. 3B ; Langmade et al., 2006; . Loss of Purkinje cell bodies was accompanied by axonal spheroid formation, dystrophic dendritic abnormalities, and microglial and astrocytic changes in affected cerebellar areas (Fig. 3D) . Although the distribution of Purkinje cell loss in the Npc1 I1061T mice was similar to that observed in the Npc1 Ϫ/Ϫ model, the degree of Purkinje cell loss at P63 was less severe than in similarly aged Npc1 Ϫ/Ϫ mice, findings consistent with delayed onset of impaired motor coordination in the knock-in compared with the knock-out model (Langmade et al., 2006) .
We then investigated whether Purkinje cells from Npc1
I1061T
mice displayed the well characterized subcellular abnormalities of NPC1 disease (Higashi et al., 1993) . Immunofluorescence staining of cerebellar sections revealed subcellular storage of cholesterol and ganglioside GM2 in Purkinje neurons from P63 Npc1 I1061T mice, similar to the pattern observed in the Npc1 Ϫ/Ϫ model (Fig. 3E) . We also observed subcellular ultrastructural pathology in these animals, with the presence of polymembranous storage bodies in Purkinje cells from P63 Npc1 I1061T mice ( Fig. 3F ; Higashi et al., 1993) . In addition, Npc1 I1061T mice exhibited cholesterol storage in CD68-positive macrophages (Fig. 4A ) and in hepatocytes (Fig. 4B) , cell types critically associated with the progression of the liver disease (Lopez et al., 2012) . Electron microscopy similarly revealed the presence of polymembranous storage bodies in both macrophages and hepatocytes (Fig. 4C) and was most abundant in layers V and VI (Fig. 5A) . A substantial portion of the metabolites localized to neuronal cell bodies; however, we also identified abnormal accumulation in meganeurites, a feature previously described in NPC disease (Fig. 5B) . To determine whether the microglia were activated in the Npc1 I1061T mice, neocortical sections were stained with CD68 and GFAP, markers that monitor macrophage infiltration in Npc1 Ϫ/Ϫ brain (Langmade et al., 2006; Lopez et al., 2012) . Immunofluorescence staining of neocortical sections also revealed an age-dependent increase in microglial activity and astrocytic reactive changes in Npc1 I1061T tissue, as seen by increased CD68 and GFAP signals (Fig. 5C ). The progression and spatial pattern of microglial activation, while delayed, is similar to that reported in the Npc1 
The murine NPC1
I1061T protein is unstable and retained in the ER In human NPC1 mutant fibroblasts, the NPC1 I1061T protein is misfolded and targeted for proteasomal degradation. As a result, the half-life of the mutant NPC1 protein is decreased, and the small amount of protein that is present is predominantly localized to the ER (Gelsthorpe et al., 2008) . We hypothesized that the murine NPC1
I1061T protein shares the same defect. To determine whether tissues from Npc1 I1061T mice have decreased NPC1 protein accumulation, we performed Western blotting of liver and brain homogenate. Npc1 I1061T mice showed dramatically decreased levels of NPC1 protein in both tissues compared with WT, which was disproportionate to the slight decrease in NPC1 mRNA expression (Fig. 6A-C) . This finding is consistent with our previous observation in human NPC1 I1061T fibroblasts, in which there was no correlation between NPC1
I1061T transcript abundance and mutant protein levels, indicating that NPC1 protein levels are principally regulated by translational or post-translational mechanisms rather than transcriptional mechanisms (Gelsthorpe et al., 2008) . In addition, the NPC1 I1061T protein demonstrated an enhanced electrophoretic mobility, suggesting a less mature glycosylation state. Most of the NPC1
I1061T protein migrates as a ϳ140 kDa band, which is the predicted weight of unmodified NPC1, whereas a small proportion of presumably glycosylated NPC1 I1061T protein appears as higher-molecular-weight bands. To determine whether murine NPC1 I1061T protein has decreased stability, we isolated hepatocytes from WT and Npc1 I1061T littermates, treated these primary cells with CHX to block new protein synthesis, and quantified levels of NPC1 protein by Western blotting. Whereas 63% of WT NPC1 protein was remaining after treatment, only 33% of NPC1 I1061T protein remained after CHX treatment (Fig.  6D) . These findings phenocopied the reduced stability of the mutant NPC1 protein in human skin fibroblasts derived from a patient homozygous for the NPC1 I1061T mutation. The kinetics of the NPC 1I1061T protein degradation in the murine hepatocytes differed slightly from that in human fibroblasts, possibly reflecting cell-or species-specific differences (Fig. 6E) . Moreover, digestion of liver and brain homogenate with endoglycosidase H, which removes immature N-linked glycan residues, revealed that a majority of murine NPC1
I1061T protein lacks mature glycosylation, indicating that it has been retained in the ER because of misfolding (Fig. 6F ) . We also found that the digested NPC1 I1061T protein from brain homogenate migrates as a higher-molecularweight band compared with liver homogenate, indicating that NPC1 I1061T protein may acquire additional post-translational modifications in this organ. It has also been previously shown that the buffers used in the digest reaction alter the apparent mobility of NPC1 bands (Gelsthorpe et al., 2008) , which explains the difference in the appearance between Fig. 6 , A and F. . Lipidomic analysis of Npc1 I1061T tissues. Lipid and sterol species were quantified from liver (A, B) and brain (C, D) homogenate via LC-MS/MS, and heat maps were generated as described in Materials and Methods. Each tile represents a single animal (n ϭ 4 per group). Z scores are represented in a gradient color scale; green represents the lowest value (Ϫ3), black represents "0" value, and red represents the highest value (ϩ3).
To determine whether the subcellular localization of NPC1
I1061T protein is altered, we performed immunofluorescence staining in MEFs. In WT MEFs, NPC1 protein colocalized with a LAMP1-positive, filipin-negative endolysosomal compartment. In contrast, in Npc1 I1061T MEFs, the mutant protein was expressed at much lower levels than WT NPC1 protein and displayed a reticular staining pattern that was distinct from filipinpositive lysosomes and most consistent with ER localization (Fig. 7) . Together, these data indicate that murine NPC1
I1061T protein, like the human mutant protein, is misfolded and targeted for ERassociated degradation, preventing its proper targeting to endolysosomes.
Cytokine activation and inflammation in tissues in
Npc1
I1061T mice A prominent feature of NPC1 disease models is profound inflammatory changes, particularly in brain tissue (Langmade et al., 2006) . We quantified inflammatory gene expression by performing RTqPCR on mRNA isolated from brain and liver tissue from Npc1 I1061T mice and WT littermates at P28, P63, and P105 (Fig. 8) . Npc1 I1061T cerebellum tissue showed increased apolipoprotein E (apoE) and GFAP expression compared with WT that was significant at P63 and P105 (for P63 and P105, p Ͻ 0.05), consistent with glial activation known to occur in response to neuronal cell death in NPC1 disease (Fig. 8A; Baudry et al., 2003) . This was accompanied by a dramatic increase in expression of cytokines (TNF␣ and MIP1␣) and markers of microglial activation (CD68 and CD11c), particularly late in disease progression (Figs. 3D, 5C, 8B) . A similar pattern of induction of inflammatory gene expression was present in liver tissue (Fig. 8C) . With the exception of apoE expression, no significant changes in cholesterol homeostatic gene expression were observed in either brain (Fig. 8A ) or liver (data not shown) tissue.
Lipid accumulation in tissues of Npc1
I1061T mice Previous studies have shown that multiple cholesterol-derived metabolites and sphingolipid species accumulate in liver and brain of the Npc1 Ϫ/Ϫ mouse model, and abundance of many species increases with disease progression (Pentchev et al., 1980; Goldin et al., 1992; Porter et al., 2010; Fan et al., 2013) . To determine whether the I1061T missense mutation led to a similar lipid storage phenotype, we broadly surveyed cholesterol-derived metabolites and sphingolipid de novo and recycling pathways in liver and brain tissue from the Npc1 I1061T , Npc1 ϩ/I1061T , and WT littermates (P14, P28, P63, and P105) and from Npc1 Ϫ/Ϫ mice and WT littermates (P49). Lipid classes quantified by tandem mass spectrometry included sphingoid bases, ceramides, sphingomyelins, monohexosylceramides and dihexosylceramides, gangliosides, sulfatides, unesterified and esterified cholesterol, and Fold change values of lipids quantified in liver and brain from Npc1 I1061T mice compared with WT mice of the same age. n ϭ 4 per group. Light gray, p Յ 0.05; dark gray, p Յ 0.01; black, p Յ 0.001; white, nonsignificant.
oxysterols. The metabolomic profiles of brain and liver tissues from Npc1 ϩ/I1061T and WT littermates were very similar, consistent with previous profiling of heterozygotes in the Npc1 Ϫ/Ϫ mouse strain ( Fig. 9; Fan et al., 2013) . The only significant differences were increased cholesteryl ester (16:0, 18:0, and 18:1) species in brain tissue in P14 and P28 Npc1 ϩ/I1061T mice (Fig. 9C,D) . In contrast, metabolomic profiling revealed marked differences between Npc1 I1061T mice and age-matched WT littermates (Fig. 9 , Table  1 (Fig. 9B) . The profound lipid storage in the suckling P14 mice likely reflects the high lipid content of the mouse milk (Silverman et al., 1992) since the lipid storage partially resolved after the mice were weaned at P21. In the liver tissue of older Npc1 I1061T mice, there was age-dependent accumulation of multiple sphingolipid species. Significant increases were found among ceramide (24:0), monohexosylceramides (16:0, 20:0, 22:0, 24:0, and 24:1), lactosylceramides (20:0 and 22:0), sphingomyelins (18:1 and 24:0), sphingosine, and gangliosides (GM2 16:0, GM2 22:0, and GM3 16:0; Fig. 9A ). The sphingolipid accumulation was accompanied by significant increases in unesterified cholesterol, 24( S)-hydroxycholesterol, and 3␤,5␣,6␤-cholestan-triol (Table  1, Fig. 9A ). Sphingolipids were also elevated in the brain tissue of the Npc1 I1061T mice, with significant increases found in lactosylceramide (20:0), sulfatide (20:0), sphinganine, and GM3 ganglioside (GM3 18:0) species (Fig. 9C) . No significant differences in cholesterol or oxysterol species were detected in bulk brain tissue.
Although the sphingolipid and cholesterol storage phenotype in the Npc1 I1061T mice was consistent with findings previously reported in the Npc1 Ϫ/Ϫ mice (Hù lková et al., 2005; Fan et al., 2013) , we were intrigued by the observation that Npc1 I1061T mice principally accumulate monohexosylceramides and lactosylceramides in brain and liver tissues, whereas Npc1 Ϫ/Ϫ mice store relatively more gangliosides (GM2 and GM3; Table 1 , Fig. 9 ). To assess whether the distinct lipid storage patterns reflected the difference between a partially functional NPC1 missense muta- Ϫ/Ϫ C57BL/6 and Balb/C strains. A, Lipid and sterol species were quantified in liver and brain homogenate from P49 Npc1 Ϫ/Ϫ C57BL/6 and Balb/C mice via LC-MS/MS, and heat maps were generated as described in Materials and Methods. Values were normalized to WT C57BL/6. Each tile represents a single animal (n ϭ 3-5 per group). Z scores are represented in a gradient color scale; green represents the lowest value (Ϫ3), black represents "0" value, and red represents the highest value (ϩ3). B, Fold change values of lipids quantified in A, normalized to WT C57BL/6 mice. Significance was calculated via Student's t test, comparing Npc1 Ϫ/Ϫ mice with their strain WT littermates. Blue, p Ͻ 0.05; green, p Ͻ 0.01; purple, p Ͻ 0.001; white, nonsignificant.
tion and a null mutation or differences in genetic background (Npc1 I1061T and Npc1 Ϫ/Ϫ mice are hosted in the C57BL/6 and BALB/c strains, respectively), we obtained brain and liver tissues from Npc1 Ϫ/Ϫ mice backcrossed into the C57BL/6 background. Metabolomic profiling was performed in P49 Npc1 Ϫ/Ϫ mice in both genetic backgrounds and demonstrated that although there are only minor differences between the BALB/c and C57BL/6 WT lipid profiles, livers from C57BL/6 Npc1 Ϫ/Ϫ mice accumulate more ceramides (16:0, 18:0, 20:0, and 24:1), monohexosylceramides (22:0 and 24:0), sphingomyelins (16:0, 18:0, 20:0, and 24:0) , sphingoid bases (SPH, S'PH, and 3-keto S'PH), gangliosides (GM2 16:0, 18:0, and 22:0; GM3 16:0 and 22:0) , free cholesterol, 24( S)-hydroxycholesterol, 4␤-hydroxycholesterol, and cholesterol ester (18:1) compared with their BALB/c Npc1 Ϫ/Ϫ counterparts (Fig. 10) . Fewer differences were seen in brain tissue, where C57BL/6 Npc1 Ϫ/Ϫ mice accumulate more ceramide (24:1), lactosylceramide (24:1), and 3␤,5␣,6␤-cholestan-triol (Fig. 10) .
Treatment with HDAC inhibitors corrects the cholesterol storage phenotype in Npc1
I1061T MEFs In recent studies, we showed that treatment of human NPC1 mutant cells with certain HDAC inhibitors, including the nonselective HDAC inhibitor SAHA, leads to clearance of excess cholesterol and other lipids from late endosomes/lysosomes and corrects the overall defect in cholesterol regulation (Pipalia et al., 2011) . These changes were accompanied by increased expression of NPC1 I1061T mutant protein. To determine whether the murine NPC1
I1061T protein in the knock-in mice responded in a similar manner as human NPC1
I1061T fibroblasts to a proteostatic therapy, we isolated MEFs from day 13.5 Npc1 I1061T and WT littermate embryos and treated them with SAHA, and filipin labeling of late endosomes/lysosomes was quantified as described previously (Pipalia et al., 2011) . Compared with DMSO vehicle controls, SAHA-treated Npc1 I1061T MEFs had reduced free cholesterol storage, as determined by filipin staining (Fig. 11 A, B) . A similar effect was observed in WT cells in which we have previously shown that half of newly synthesized NPC1 is normally degraded (Gelsthorpe et al., 2008) . We found that the decrease in lysosomal-free cholesterol in SAHA-treated Npc1
I1061T MEFs was attributable to an increase in the abundance of NPC1
I1061T protein, as shown by Western blot analysis (Fig. 11C) . We also observed that SAHA treatment increases the amount of high-molecular-weight NPC1 I1061T protein, which likely corresponds to glycosylated, mature protein that is appropriately localized to the lysosome. A trend toward increased NPC1 protein was likewise observed in the SAHA-treated WT MEFs.
Discussion
Herein, we generated and characterized a novel NPC1 disease model, the Npc1 I1061T knock-in mouse. Introduction of the I1061T missense mutation into the murine NPC1 locus destabilized the NPC1 protein and prevented targeting to late endosomes/lysosomes, mimicking the effects of this mutation in human fibroblasts. Phenotypically, the reduced lifespan, altered growth curves, and progressive decline in motor coordination were all consistent with NPC1 disease, though milder than the severe infantile form of the disease modeled by the BALB/c Npc1 Ϫ/Ϫ mouse. Similar to the Npc1
mice, we identified a progressive and complex neuropathology, including stereotypic Purkinje cell loss in the cerebella of Npc1 I1061T mice, which was antecedent to motor dysfunction and is a neuropathological hallmark of the disease (Higashi et al., 1993; . The neurological phenotype was accompanied by astrogliosis, inflammatory gene expression, and storage of cholesterol-derived and sphingolipid species in liver and brain tissues, mirroring the changes reported in human NPC1 disease (Vanier, 1983 Walkley and Suzuki, 2004; Cologna et al., 2014) . In summary, this novel mouse model faithfully recapitulates disease caused by the human NPC1
I1061T mutation and provides a powerful tool for preclinical evaluation of proteostatic therapies for NPC1 disease. Moreover, the Npc1
I1061T knock-in mouse may have broader use as a more general model for the study of protein misfolding in vivo. I1061T protein is misfolded and targeted for degradation (Gelsthorpe et al., 2008) . The immunofluorescence staining pattern for the NPC1 I1061T protein, which revealed that the majority of the mutant protein failed to colocalize with LAMP1, a late endosomal/lysosomal marker, also supports a model in which the mutant protein is retained within the ER. Intriguingly, we found differences in the electrophoretic mobility of WT and NPC1
I1061T proteins from liver and brain tissues. Endoglycosidase H and PNGase F digestion of WT protein from these tissues suggests that the NPC1 protein may be differentially glycosylated in the liver and brain. The NPC1 I1061T protein is sensitive to both glycosidases in both tissues, suggesting that its impaired folding prevents trafficking through the ER and the addition of N-linked sugar residues. The higher molecular weight of NPC1
I1061T in brain tissue also suggests this protein may be subject to other post-translational modifications. At present, the relevance of such tissue-specific differences in protein modification to normal physiology or disease pathophysiology is uncertain.
CNS lipid storage is central to the pathophysiology of NPC disease and precedes the inflammation and microglial activation that accompany neuronal loss (Reid et al., 2004) . Neuropathological assessment and metabolomic analysis of brains from Npc1 I1061T knock-in mice revealed age-dependent accumulation of a broad range of sphingolipid classes, notably sphingoid bases, monohexosylceramides and dihexosylceramides, sphingomyelins, and gangliosides. This pattern of storage is similar to the brain tissue profile previously reported for Npc1 Ϫ/Ϫ mice (Fan et al., 2013) , demonstrating that the knock-in mouse faithfully models NPC1 disease. Although the general consensus is that the primary defect in NPC1 disease is impaired endolysosomal cholesterol export, the cholesterol accumulation is invariably accompanied by secondary storage of sphingolipids (Pentchev et al., 1980 (Pentchev et al., , 1984 Vanier, 1983 Goldin et al., 1992) , perhaps caused by the well established biophysical association of cholesterol and sphingolipids in membrane bilayers. The finding that miglustat, a partial inhibitor of glucosylceramide synthase, provides disease amelioration in NPC1 animal models and the fact that limiting synthesis of complex gangliosides leads to reduced cholesterol accumulation imply a critical role for sphingolipid storage in disease pathogenesis (Zervas et al., 2001; Gondré-Lewis et al., 2003; Zhou et al., 2011; Stein et al., 2012; Lee et al., 2014) . In contrast to the sphingolipid species, unesterified cholesterol levels in bulk brain tissue are not elevated. Rather, cholesterol storage is evident only by cytochemical analysis of brain tissue sections, predominantly in nuclei containing large neurons that have high obligate rates of cholesterol flux (Dietschy and Turley, 2004) .
The Npc1 I1061T mice similarly exhibit profound lipid storage in peripheral tissues that is a prominent feature in NPC1 animal models and human NPC1 disease (Pentchev et al., 1980; Vanier, 1983; Zervas et al., 2001; Maue et al., 2012; Fan et al., 2013) . As in the brain tissue, sphingolipid storage in liver tissue steadily increases from P28 to P105, which correlates with disease progression, but, in contrast to brain tissue, is accompanied by increased unesterified cholesterol in bulk tissue. Along with increased cholesterol stores, there is an attendant elevation of 3␤,5␣,6␤-cholestan-triol, a nonenzymatic oxidation product that is an NPC1-specific biomarker of disease (Porter et al., 2010; Jiang et al., 2011) , which reflects the unique intersection of elevated unesterified cholesterol and oxidative stress in NPC disease (Zampieri et al., 2009; Smith et al., 2009 ).
An unexpected finding was the massive lipid storage in the suckling P14 knock-in mice. The elevation was transient, as cholesterol and sphingolipid content were reduced after weaning (e.g., in P28 mice), strongly implicating the high lipid content of the mouse milk (Silverman et al., 1992) . Moreover, the lipid storage in the suckling mice was observed in liver but not in brain tissue, further supporting an exogenous origin for the lipid, since dietary cholesterol does not cross the blood-brain barrier (Dietschy and Turley, 2004) . The lipid storage phenotype in liver tissue in the neonatal knock-in mice closely mirrors the profound cholesterol storage in human NPC1 neonates, approximately half of whom present with prolonged jaundice or hepatosplenomegaly .
The genetic background of Npc1 I1061T mice appears to have profound modulatory effects on the NPC1 disease phenotype. Initially, the knock-in mice were backcrossed in the BALB/c strain to permit comparison with the Npc1 Ϫ/Ϫ mice in the same background. Although the NPC1 disease phenotype (e.g., tremor and reduced lifespan) was readily apparent in the mice in the mixed 129/BL6 background, this phenotype was markedly attenuated once backcrossed into the BALB/c background (our unpublished observations A. Lieberman and D. Ory). In this genetic background, there was no overt neurological phenotype in 6-month-old mice, and disease was only detectable neuropathologically (data not shown), prompting us to re-establish the knock-in mice in the more permissive C57BL/6 background. Consistent with this finding, metabolomic profiling of the Npc1 Ϫ/Ϫ mice revealed significant differences in the extent of cholesterol and sphingolipid storage between the different genetic backgrounds. Compared with Npc1 Ϫ/Ϫ mice in the BALB/c background, Npc1 Ϫ/Ϫ mice in the C57BL/6 background displayed an increased accumulation of ceramide species, sphingomyelins, sphingoid bases, gangliosides, free cholesterol, and oxysterols in peripheral tissues. We hypothesize that the BALB/c strain harbors a modifier gene that confers protection against NPC disease (Collins et al., 2006) . This putative modifier gene could help stabilize the NPC1 I1061T protein in the ER by modulating endogenous chaperones (Yang et al., 2013) , allowing more time for the NPC1 I1061T protein to achieve proper conformation for entry into the post-ER secretory pathway, and ultimately be targeted to endolysosomes. Alternatively, the modifier gene might act to decrease subcellular lipid accumulation, either by regulating synthesis/processing of sphingolipids or by facilitating endolysosomal cholesterol release through NPC1-independent trafficking pathways Cianciola et al., 2013) . This variable penetrance of the NPC1 phenotype in the different genetic backgrounds will provide an opportunity in future studies to identify modifier genes that contribute to NPC1
I1061T protein stabilization. The Npc1 I1061T knock-in mouse presents a unique tool to assess candidate proteostatic therapies in vivo. Whereas the Npc1 Ϫ/Ϫ mouse model continues to be a valuable reagent in understanding and treating NPC disease, it is not amenable to testing therapies aimed at modulation of expression and/or post-
